nice to see $GHRS win for BVF and RA I remember when co just launched People remember the early days of ATAI and Compass?

which firms returns do you think the least number of biotech professionals have seen, the most secretive/hidden?

. Meanwhile Saqib chilling 10b5-1 hitting no conferences to attend, no earnings calls to host , no approval launch conversations to be had. $swtx

parsing through old files...found this! good times. Akash note $SLRN $ALMS

this is so funny I can’t

TRAITS OF A GOOD ANALYST (1/2) Over the past several years I’ve had 6 analysts who at some point reported me, and have interacted with countless more.  These are the traits I’ve found to be most correlated with long term success. They probably aren’t what you think. A 🧵 What I

Can anyone tell me what value $OVID has had for shareholders or the patient community for the past decade vs. Levin's committments (BIO chair, boards). To you is it a) neuro is really hard, b) mid execution, c) some other factor or d) I'm being too harsh

can the $PFE board fire Albert so this stock can start getting out of limbo thanks

🔥

$SWTX don't worry guys Centerview can't and won't allow the $47 to fly...it messes up precedent on premium completely.

Sometimes when an analyst or investor sees the COO of a public biotech company spending a couple of weeks hiking to Everest basecamp while its stock is $0.30, they think that maybe they should be working harder to fix the situation the company is in.

who is more powerful?

Hold $XENE until buyout

Livmarli and Bylvay updated labels interesting what happened to Ron even $MIRM $ALBO

short $ABVX no durability

actually not going to play $ABVX catalyst...induction might hit (though am not personally convinced and don't love rr) but I am convinced maintenance misses can find better rr elsewhere for record was hoping drug works for pts but data may suggest otherwise